These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24903940)

  • 1. Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa.
    Sunpath H; Winternheimer P; Cohen S; Tennant I; Chelin N; Gandhi RT; Murphy RA
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):689-93. PubMed ID: 24903940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
    Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
    PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
    Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1170-6. PubMed ID: 22250979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
    Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
    Nijland HM; L'homme RF; Rongen GA; van Uden P; van Crevel R; Boeree MJ; Aarnoutse RE; Koopmans PP; Burger DM
    AIDS; 2008 May; 22(8):931-5. PubMed ID: 18453852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
    Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L
    Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
    Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H
    PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.
    Rabie H; Rawizza H; Zuidewind P; Winckler J; Zar H; Van Rie A; Wiesner L; McIlleron H
    J Antimicrob Chemother; 2019 Aug; 74(8):2347-2351. PubMed ID: 31081020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.
    McIlleron H; Ren Y; Nuttall J; Fairlie L; Rabie H; Cotton M; Eley B; Meyers T; Smith PJ; Merry C; Maartens G
    Antivir Ther; 2011; 16(3):417-21. PubMed ID: 21555825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
    Kendall MA; Lalloo U; Fletcher CV; Wu X; Podany AT; Cardoso SW; Ive P; Benson CA
    Clin Infect Dis; 2021 Aug; 73(4):706-715. PubMed ID: 34398956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
    Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda.
    Mulindwa F; Castelnuovo B; Kirenga B; Kalibbala D; Haguma P; Muddu M; Semitala FC
    BMC Infect Dis; 2021 Aug; 21(1):822. PubMed ID: 34399706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
    Perry ME; Taylor GP; Sabin CA; Conway K; Flanagan S; Dwyer E; Stevenson J; Mulka L; McKendry A; Williams E; Barbour A; Dermont S; Roedling S; Shah R; Anderson J; Rodgers M; Wood C; Sarner L; Hay P; Hawkins D; deRuiter A
    HIV Med; 2016 Jan; 17(1):28-35. PubMed ID: 26200570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
    Reitz C; Coovadia A; Ko S; Meyers T; Strehlau R; Sherman G; Kuhn L; Abrams EJ
    J Infect Dis; 2010 Apr; 201(8):1121-31. PubMed ID: 20214476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
    L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
    AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
    Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.